Endometrial Cancer
Conditions
Keywords
Genetic testing
Brief summary
In order to formulate strategies to improve adherence to best practice guidelines, as well as utilization of novel therapies, investigators must understand current practice patterns surrounding tumor genetic testing in endometrial cancer. The aim is to survey a representative sample of gynecologic oncologists who belong to the society of gynecologic oncology, via an email survey, to better understand current practices surrounding tumor genetic testing as well as determine if there have been any changes to practice since the publication of recent trials on the use of immune-checkpoint inhibitors in endometrial cancer.
Detailed description
Primary Objective: Proportion of physicians reporting the use of different tumor genetic testing strategies among newly diagnosed endometrial cancer patients. Secondary Objectives: * Explore the use of informed consent in tumor genetic testing in endometrial cancer * Explore clinician confidence in utilizing tumor genetic testing to guide treatment decisions. * Explore the impact of recent publications regarding immunotherapy on the use of tumor genetic testing in endometrial cancer.
Interventions
OTHERSurveys
Survey on practice patterns surrounding tumor genetic testing in endometrial cancer.
Sponsors
National Cancer Institute (NCI)
Wake Forest University Health Sciences
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
* Member of the Society of Gynecologic Oncology * Gynecologic Oncologist or Gynecologic Oncology Fellow-in-Training
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of providers reporting the use of different tumor genetic testing strategies among newly diagnosed endometrial cancer patients | 4 months | The primary outcome is to estimate the percentage of providers who report the use of different tumor testing strategies. Investigators will calculate the frequencies of responses to each testing strategy and then compare the percentage of physicians who choose different strategies, using a chi-square or Fisher's exact test. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of providers using different strategies of informed consent in tumor genetic testing in endometrial cancer | 4 months | Investigators will calculate the number of frequencies of different tumor testing informed consent strategies among physicians. |
| Number of providers reporting confidence in utilizing tumor genetic testing to guide treatment decisions | 4 months | Investigators will calculate the number of providers who are very confident, moderately confident, a little confident or not at all confident in their ability to explain tumor testing strategies and results. |
| Number of providers who change their counseling or testing strategies for endometrial cancer | 4 months | Investigators will compare the number of providers who have changed their counseling or testing strategy based on their familiarity with recent publications regarding immune-checkpoint inhibitors in advanced and recurrent endometrial cancer using a chi-square or Fisher's exact test. |
Countries
United States
Outcome results
None listed